Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid

Biochemical Pharmacology

Volumn 75, Issue 3, 2008, Pages 668-676

  Stolfi, Carmine ^a   Fina, Daniele ^a   Caruso, Roberta ^a   Caprioli, Flavio ^a   Sarra, Massimiliano ^a   Fantini, Massimo Claudio ^a   Rizzo, Angelamaria ^a   Pallone, Francesco ^a   Monteleone, Giovanni ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

5 ASA; Colon cancer; COX 2

Indexed keywords

CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; MESALAZINE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERLEUKIN-1BETA; MESALAMINE; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 37849007849     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.09.020     Document Type: Article

References (45)

1. Eaden J. Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther 20 Suppl. 4 (2004) 24-30
2. Huls G., Koornstra J.J., and Kleibeuker J.H. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 362 9379 (2003) 230-232
3. Koehne C.H., and Dubois R.N. COX-2 inhibition and colorectal cancer. Semin Oncol 31 2 Suppl. 7 (2004) 12-21
4. Smalley W., Ray W.A., Daugherty J., and Griffin M.R. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 159 2 (1999) 161-166
5. Baron J.A., Sandler R.S., Bresalier R.S., Quan H., Riddell R., Lanas A., et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131 6 (2006) 1674-1682
6. Arber N., Eagle C.J., Spicak J., Racz I., Dite P., Hajer J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355 9 (2006) 885-895
7. Bertagnolli M.M., Eagle C.J., Zauber A.G., Redston M., Solomon S.D., Kim K., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355 9 (2006) 873-884
8. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 26 (2000) 1946-1952
9. Vane J.R., Bakhle Y.S., and Botting R.M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38 (1998) 97-120
10. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B., et al. Cyclooxygenase in biology and disease. FASEB J 12 12 (1998) 1063-1073
11. Tsujii M., Kawano S., and DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94 7 (1997) 3336-3340
12. Eaden J. Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther 18 Suppl. 2 (2003) 15-21
13. Kohno H., Suzuki R., Sugie S., and Tanaka T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 5 1 (2005) 46
14. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 5 (1996) 803-809
15. Kashfi K., and Rigas B. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol 70 7 (2005) 969-986
16. Williams J.L., Nath N., Chen J., Hundley T.R., Gao J., Kopelovich L., et al. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res 63 22 (2003) 7613-7618
17. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 11 (2005) 1092-1102
18. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 11 (2005) 1071-1080
19. Guslandi M. Exacerbation of inflammatory bowel disease by nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors: fact or fiction?. World J Gastroenterol 12 10 (2006) 1509-1510
20. Bernstein C.N., Eaden J., Steinhart A.H., Munkholm P., and Gordon P.H. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Inflamm Bowel Dis 8 5 (2002) 356-361
21. Rubin D.T., LoSavio A., Yadron N., Huo D., and Hanauer S.B. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 4 11 (2006) 1346-1350
22. Reinacher-Schick A., Schoeneck A., Graeven U., Schwarte-Waldhoff I., and Schmiegel W. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 24 3 (2003) 443-451
23. Fina D., Franchi L., Caruso R., Peluso I., Naccari G.C., Bellinvia S., et al. 5-Aminosalicylic acid enhances anchorage-independent colorectal cancer cell death. Eur J Cancer 42 15 (2006) 2609-2616
24. Narisawa T., and Fukaura Y. Prevention by intrarectal 5-aminosalicylic acid of N-methylnitrosourea-induced colon cancer in F344 rats. Dis Colon Rectum 46 7 (2003) 900-903
25. Brown W.A., Farmer K.C., Skinner S.A., Malcontenti-Wilson C., Misajon A., and O'Brien P.E. 5-Aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig Dis Sci 45 8 (2000) 1578-1584
26. Monteleone G., Franchi L., Fina D., Caruso R., Vavassori P., Monteleone I., et al. Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. Cell Death Differ 13 2 (2006) 202-211
27. Bos C.L., Diks S.H., Hardwick J.C., Walburg K.V., Peppelenbosch M.P., and Richel D.J. Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis 27 12 (2006) 2371-2382
28. Rousseaux C., Lefebvre B., Dubuquoy L., Lefebvre P., Romano O., Auwerx J., et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 201 8 (2005) 1205-1215
29. Grosch S., Tegeder I., Niederberger E., Brautigam L., and Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15 14 (2001) 2742-2744
30. Tong X., Yin L., Joshi S., Rosenberg D.W., and Giardina C. Cyclooxygenase-2 regulation in colon cancer cells: modulation of RNA polymerase II elongation by histone deacetylase inhibitors. J Biol Chem 280 16 (2005) 15503-15509
31. Liu W., Reinmuth N., Stoeltzing O., Parikh A.A., Tellez C., Williams S., et al. Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res 63 13 (2003) 3632-3636
32. Strober W., Fuss I., and Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 117 3 (2007) 514-521
33. Shureiqi I., Chen D., Lotan R., Yang P., Newman R.A., Fischer S.M., et al. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 60 24 (2000) 6846-6850
34. Tsuji S., Kawano S., Sawaoka H., Takei Y., Kobayashi I., Nagano K., et al. Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. Prostaglandins Leukot Essent Fatty Acids 55 3 (1996) 179-183
35. Singer I.I., Kawka D.W., Schloemann S., Tessner T., Riehl T., and Stenson W.F. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115 2 (1998) 297-306
36. Sheu M.L., Chao K.F., Sung Y.J., Lin W.W., Lin-Shiau S.Y., and Liu S.H. Activation of phosphoinositide 3-kinase in response to inflammation and nitric oxide leads to the up-regulation of cyclooxygenase-2 expression and subsequent cell proliferation in mesangial cells. Cell Signal 17 8 (2005) 975-984
37. Jin S.H., Kim T.I., Yang K.M., and Kim W.H. Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR. Eur J Pharmacol 558 1-3 (2007) 14-20
38. Kaiser G.C., Yan F., and Polk D.B. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 116 3 (1999) 602-609
39. Fichera A., Little N., Jagadeeswaran S., Dougherty U., Sehdev A., Mustafi R., et al. Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Cancer Res 67 2 (2007) 827-835
40. Mbonye U.R., Wada M., Rieke C.J., Tang H.Y., Dewitt D.L., and Smith W.L. The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system. J Biol Chem 281 47 (2006) 35770-35778
41. Sheng G.G., Shao J., Sheng H., Hooton E.B., Isakson P.C., Morrow J.D., et al. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology 113 6 (1997) 1883-1891
42. Chan T.A., Morin P.J., Vogelstein B., and Kinzler K.W. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95 2 (1998) 681-686
43. Bus P.J., Nagtegaal I.D., Verspaget H.W., Lamers C.B., Geldof H., Van Krieken J.H., et al. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era?. Aliment Pharmacol Ther 13 11 (1999) 1397-1402
44. Reinacher-Schick A., Seidensticker F., Petrasch S., Reiser M., Philippou S., Theegarten D., et al. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy 32 3 (2000) 245-254
45. Frieri G., Pimpo M.T., Palumbo G.C., Onori L., Viscido A., Latella G., et al. Rectal and colonic mesalazine concentration in ulcerative colitis: oral versus oral plus topical treatment. Aliment Pharmacol Ther 13 11 (1999) 1413-1417